ASH 2023 | Dasatinib plus venetoclax in ECP-CML: insights from a Phase II study
Fadi Haddad, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase II trial (NCT02689440) investigating the safety and efficacy of dasatinib with venetoclax in patients with early chronic phase chronic myeloid leukemia (ECP-CML). The primary endpoint of the study was the rate of major molecular response (MMR) by 12 months of receiving the combination or 15 months from the start of therapy. The survival outcomes seen with this therapeutic approach were highly encouraging. However, the response rates observed were not higher than those historically recorded for dasatinib monotherapy. The most common adverse event experienced with this combination was neutropenia, which was managed through venetoclax dose adjustment. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
